雌激素受体低表达(1%-10%)早期乳腺癌中内分泌治疗的省略
该研究利用美国国家癌症数据库,纳入7018例接受化疗的高危I-III期ER低表达(1%-10%)早期乳腺癌患者,分析省略内分泌治疗与总生存的关系。中位随访3年,多因素分析显示省略内分泌治疗与死亡风险升高相关(HR 1.23),在ER 6%-10%及新辅助化疗后残留病灶者中影响更明显。
要点
- ER低表达早期乳腺癌省略内分泌治疗与总生存显著变差相关(HR 1.23)。
- ER 6%-10%者省略内分泌治疗与死亡风险升高相关(HR 1.42),ER 1%-5%者未达统计学显著(HR 1.15)。
- 新辅助化疗后残留病灶者省略内分泌治疗与更差总生存相关(HR 1.26),病理完全缓解者无显著差异(HR 1.06)。
核心结论
- 在ER低表达早期乳腺癌中,省略内分泌治疗与显著更差的总生存相关,尤其在新辅助化疗后残留病灶及ER 6%-10%者中。
- 在前瞻性数据可用之前,应就内分泌治疗的潜在获益对ER低表达乳腺癌患者进行咨询。
研究设计与样本
- 利用美国国家癌症数据库开展的队列研究,纳入高危I-III期ER低表达(免疫组化1%-10%)且接受(新)辅助化疗的乳腺癌患者。
- 共10362例I-III期ER低表达乳腺癌患者,其中7018例接受化疗并符合纳入标准。
- 以内分泌治疗启动作为时间依赖协变量,采用Cox比例风险回归分析总生存。
主要发现
- 12个月时内分泌治疗省略率为42%,在孕激素受体阴性、人表皮生长因子受体2阴性、分级较高(2/3级)及Ki-67较高(≥20%)的患者中更常见(均P<.001),在接受新辅助化疗者中也更常见(P<.001)。
- 中位随访3年,观察到586例死亡。
- 多因素分析中,省略内分泌治疗与更高的死亡风险相关(HR 1.23,95%CI 1.04-1.46,P=.02)。
- ER 1%-5%者省略内分泌治疗与死亡风险相关(HR 1.15,95%CI 0.91-1.45,P=.24),ER 6%-10%者(HR 1.42,95%CI 1.00-2.02,P=.048)。
- 接受新辅助化疗者(n=4377,62%)中,省略内分泌治疗在有残留病灶者与更差总生存相关(HR 1.26,95%CI 1.00-1.57,P=.046),在达到病理完全缓解者中无显著差异(HR 1.06,95%CI 0.62-1.80,P=.84)。
临床怎么用
- 在前瞻性数据可用之前,应就内分泌治疗的潜在获益对ER低表达乳腺癌患者进行咨询。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Adjuvant endocrine therapy (ET) improves overall survival (OS) in estrogen receptor (ER)-positive early-stage breast cancer (BC). However, the benefit of ET for those with ER-low BC (ER 1%-10%) is unclear. METHODS: Using the National Cancer Database, we studied patients with high-risk stage I to III, ER-low BC (defined as immunohistochemistry 1%-10%) who received (neo)adjuvant chemotherapy and did or did not initiate ET. OS was analyzed with ET initiation as a time-dependent covariate using Cox proportional hazards regression. RESULTS: Of 10,362 patients with stage I to III ER-low BC, 7,018 received chemotherapy and met inclusion criteria. ET omission was 42% at 12 months and more common in patients with tumors that were progesterone receptor-negative, human epidermal growth factor receptor 2-negative, higher-grade (grade 2/3) and higher Ki-67 (≥20%; all P < .001) and those who received neoadjuvant chemotherapy (NAC; P < .001). With a median follow-up of 3 years, 586 deaths were observed. In a multivariable analysis, ET omission was associated with a higher risk of death (hazard ratio [HR], 1.23 [95% CI, 1.04 to 1.46]; P = .02), with a greater impact in those with higher ER levels: ER 1%-5% (HR, 1.15 [95% CI, 0.91 to 1.45]; P = .24) versus ER 6%-10% (HR, 1.42 [95% CI, 1.00 to 2.02]; P = .048). Among patients treated with NAC (n = 4,377, 62%), ET omission was associated with worse OS in those with residual disease (RD; HR, 1.26 [95% CI, 1.00 to 1.57]; P = .046) but not in those who achieved a pathologic complete response (HR, 1.06 [95% CI, 0.62 to 1.80]; P = .84). CONCLUSION: In ER-low, early-stage BC, ET omission is associated with significantly worse OS, especially in patients with RD after NAC and those with higher (6%-10%) ER levels. Until prospective data are available, patients with ER-low BC should be counseled regarding the potential benefit of ET.
引用
- Choong GM, Hoskin TL, Boughey JC, et al. Endocrine Therapy Omission in Estrogen Receptor-Low (1%-10%) Early-Stage Breast Cancer. J Clin Oncol. 2025. PMID: 40215443. doi:10.1200/JCO-24-02263
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。